|1.||Cortes, Jorge: 167 articles (10/2015 - 05/2002)|
|2.||Kantarjian, Hagop: 138 articles (11/2015 - 02/2002)|
|3.||Hochhaus, Andreas: 108 articles (09/2014 - 02/2002)|
|4.||Baccarani, Michele: 87 articles (09/2015 - 02/2002)|
|5.||O'Brien, Susan: 86 articles (11/2015 - 05/2002)|
|6.||Druker, Brian J: 84 articles (03/2015 - 01/2002)|
|7.||Kantarjian, Hagop M: 79 articles (09/2015 - 03/2002)|
|8.||Saglio, Giuseppe: 76 articles (09/2015 - 02/2002)|
|9.||Breccia, Massimo: 73 articles (09/2015 - 04/2004)|
|10.||Alimena, Giuliana: 69 articles (09/2015 - 04/2004)|
|1.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/01/2015 - "Imatinib mesylate (IM) remains the treatment of choice for chronic myeloid leukemia (CML) showing a remarkable efficacy and offers a perspective for long disease-free survival. "
11/01/2014 - "Imatinib mesylate (IM) has so far been the standard of care for treating chronic myeloid leukemia (CML), but the initial striking efficacy of this drug has been overshadowed by the development of clinical resistance, which may in part be caused by pharmacogenetic variability. "
02/01/2012 - "Targeted treatment of chronic myelogenous leukemia using imatinib has dramatically improved patient outcome. "
05/01/2011 - "Imatinib mesylate has shown remarkable efficacy in the treatment of patients in the chronic phase of chronic myeloid leukemia. "
02/01/2011 - "The advent of imatinib has dramatically improved outcomes in patients with chronic myelogenous leukemia (CML). "
04/01/2006 - "The most effective treatment for unresectable tumors is imatinib mesylate, based on two phase II trials. "
07/01/2015 - "Most GISTs that cannot be cured by surgery respond to molecularly targeted therapy (e.g., with imatinib); however, tumor cells persist in almost all patients and eventually acquire drug-resistant mutations. "
12/01/2013 - "Although meaning of primary systemic therapy for GIST was not established, it was shown that medicating Imatinib to the high-level partial advance GIST before an operation may become an effective cure which avoids an extended operation and makes complete resection of a tumor possible."
01/01/2013 - "Thus, imatinib inhibits multiple novel chemoresistance pathways, which indicates that it may be effective in reversing intrinsic and acquired resistance in cancers containing highly active c-Abl and Arg, a critical step in effectively treating metastatic disease. "
09/01/2007 - "We report here two patients with metastatic GIST who developed pelvic bone marrow focal lesions visible on MRI examinations, while Imatinib dramatically improved other tumor sites. "
|3.||Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
06/01/2015 - "The prognosis of advanced gastrointestinal stromal tumors (GISTs) was dramatically improved in the era of imatinib. "
08/01/2009 - "Despite initial efficacy of imatinib mesylate in most gastrointestinal stromal tumor (GIST) patients, many experience primary/secondary drug resistance. "
01/01/2006 - "Although most patients with gastrointestinal stromal tumor (GIST) treated with imatinib mesylate achieve remission or disease stabilization, a significant proportion show progressive disease (PD) with or without initial favorable responses. "
12/01/2003 - "Although complete responses have seldom been seen up until now, imatinib has proven to be extremely effective in the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumors."
09/01/2012 - "Imatinib was proven to be effective for the adjuvant treatment of localized, surgically excised, gastrointestinal stromal tumors (GIST). "
01/01/2010 - "From May 2005 to September 2009, we treated 42 patients (40 years; range 16-69) with Philadelphia chromosome (Ph+) positive in chronic phase CML with oral imatinib mesylate at daily doses of 400 mg. Overall survival (OS) and frequency of complete or major cytogenetic remission (CCR/MCR) were evaluated. "
03/01/2005 - "Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib."
05/01/2012 - "All 1,063 patients selected met the following inclusion criteria: aged 18 or older and in chronic phase at the time of diagnosis, Philadelphia chromosome and/or BCR-ABL positive, received first-line treatment with imatinib, and not enrolled in a randomized clinical trial during the period of retrospective review. "
01/01/2015 - "On the basis of 1151 Philadelphia chromosome positive chronic phase patients of the randomized CML-study IV, we examined the incidence of newly arising ACA under imatinib treatment with regard to the p210BCR-ABL breakpoint variants b2a2 and b3a2. "
01/01/2013 - "DESIGN, PATIENTS, AND INTERVENTION: This study assessed the effects of high-dose (600 mg/d) imatinib on bone parameters in newly diagnosed chronic-phase Philadelphia chromosome-positive CML patients (n = 11) enrolled in the TIDEL II study. "
04/01/2015 - "Although imatinib is an effective treatment for CML and most patients treated with imatinib do attain some form of remission, imatinib does not completely eradicate all leukemia cells, and if treatment is stopped, all patients eventually relapse (Cortes, 2005). "
01/01/2004 - "Although Imatinib, the first molecularly targeted drug developed for CML has achieved a remarkable success, the emergence of resistance to this agent mitigates the prospect of a cure for this leukemia. "
07/01/2015 - "The patient was treated with imatinib and achieved complete clinical remission of his leukemia and the GEH. "
11/01/2008 - "Treatment with imatinib is very effective in Bcr-Abl positive leukemia. "
05/01/2011 - "The simulations presented in this paper imply that treatment programs that involve strategic treatment interruptions may prevent leukemia from relapsing and may prevent remission for significantly longer than continuous imatinib treatment. "
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||dasatinib (BMS 354825)
|5.||4- methyl- N- (3- (4- methylimidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- pyridin- 3- ylpyrimidin- 2- yl)amino)benzamide (nilotinib)
|7.||Bcr-Abl tyrosine kinase
|8.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|9.||Interferon-alpha (Interferon Alfa)
|1.||Drug Therapy (Chemotherapy)
|2.||Stem Cell Transplantation
|4.||Hematopoietic Stem Cell Transplantation